Recombinant Mouse Antibody (ATN615) is capable of binding to UPAR, expressed in Chinese Hamster Ovary cells (CHO). This antibody binds to uPAR in vitro with high affinity (K(d) approximately 1 nM) and does not interfere with uPA binding to uPAR.
Figure 1 Immunoprecipitation of AGM suPAR clones using ATN-615 and ATN-658.
A. Single point mutants were introduced into AGM suPAR such that a single amino acid was changed from the AGM sequence to the human uPAR sequence and the proteins expressed and purified as described in the Materials and Methods.
Xu, X. , Cai, Y. , Wei, Y. , Donate, F. , Juarez, J. , & Parry, G. , et al. (2014). Identification of a new epitope in upar as a target for the cancer therapeutic monoclonal antibody atn-658, a structural homolog of the upar binding integrin cd11b (αm). Plos One, 9(1), e98490.
Zhu, Ke, et al. "The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease." Science Translational Medicine 15.714 (2023): eabq6492. https://doi.org/10.1126/scitranslmed.abq6492
This study investigates the role of the D2D3 form of the soluble urokinase plasminogen activator receptor (suPAR) in the development of diabetes and kidney disease. The research found that D2D3 acts as an immunotoxin, leading to kidney disease and insulin-dependent diabetes mellitus in transgenic mice fed a high-fat diet. These mice exhibited symptoms such as microalbuminuria, elevated serum creatinine, glomerular hypertrophy, decreased insulin and C-peptide levels, impaired glucose-stimulated insulin secretion, and reduced pancreatic β cell mass. The study demonstrated that targeting D2D3 could potentially serve as a therapeutic approach for treating kidney diseases and insulin-dependent diabetes mellitus.
Creative Biolabs played a crucial role in this study by providing the anti-uPAR monoclonal antibodies used for immunoprecipitation and Western blot analyses. Specifically, the anti-uPAR antibody ATN615 (Cat#: PABC-130) from Creative Biolabs was utilized to detect the presence of D2D3 in human sera and mouse samples. These products were instrumental in identifying the pathogenic role of D2D3 and validating the effectiveness of anti-uPAR antibody treatment in restoring β cell mass and function in D2D3 transgenic mice. The contributions of Creative Biolabs' reagents were vital in enabling the detailed examination of D2D3's impact on kidney and pancreatic functions.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-1024 | Recombinant Anti-uPAR Antibody | WB, IP, FuncS | IgG |
MHH-1024 | Recombinant Human Anti-uPAR Antibody | ELISA, IP, FuncS | IgG |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# PABC-130, RRID: AB_3111577)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.